An authoritative database of FDA’s fast-tracked medical devices. STAT Reports blend data insights with qualitative observations on pivotal life sciences topics.

At STAT, our mission is to deliver trusted, tough-minded journalism on the business of making medicines, health tech, science, public health, hospitals, and insurance.

Don't Miss STAT Staff We wish we’d written that: STAT staffers share their favorite stories of 2025 First Opinion Neil Gaffin The complicated truth about urinary tract infections in the elderly

Our price covers the cost of daily coverage, two daily STAT+ newsletters, free access to exclusive subscriber only virtual events, discounts to STAT events and summits, and additional benefits.

A STAT Examination Daniel Payne, Chelsea Cirruzzo, and Helen Branswell Trump administration’s plan to shrink vaccine schedule sends health sector scrambling Morning Rounds Theresa Gaffney

STAT’s annual Monday evening event at JPM examines the political, social, and scientific forces reshaping health care in the year ahead.

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Learn More. Cancel anytime. Interested in a group rate? Contact us.

STAT coverage and analysis of top pharmaceutical companies, from clinical trials to FDA approvals, from startups to Big Pharma mergers and acquisitions.

Health Gary Marshall Best of STAT 2025 Politics Daniel Payne The 3 biggest issues to watch in vaccine policy in 2026 Pharma John Wilkerson and Elaine Chen

Curious to see what our recent summits were like? Check out our last summit, 2025 STAT Summit, to see featured speakers, session information, and coverage highlights.